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Stlmmary 
The ~rrent vacdne against tuberculosis, Mycobacterium boris strain baciUe Calmette-Guerin (BCG), 
offers potential advantages as a live, innately immunogenic vaccine vehicle for the expression 
and delivery of protective recombinant antigens (Stover, C. K., V. F. de la Cruz, T. R. Fuerst, 
J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull 
et al. 1991. Nature[Lond].  351:456; Jacobs, W. R., Jr., S. B. Snapper, L. Lugosi and B. R. Bloom. 
1990.  Curt.  Top Microbiol. Iramunol.  155:153; Jacobs, W. R., M. Tuckman, and B. R.  Bloom. 
1987. Nature [Long]. 327:532); but as an attenuated intracdlular bacterium residing in macrophages, 
BCG would seem to be best suited for eliciting cellular responses and not humoral responses. 
Since bacterial lipoproteins are often among the most immunogenic of bacterial antigens, we 
tested whether BCG expression of a target antigen as a membrane-associated lipoprotein could 
enhance the potential for a recombinant BCG vaccine to elicit high-titered protective antibody 
responses to target antigens. Immunization of mice with recombinant BCG vaccines expressing 
the outer surface protein A (OspA) antigen of  Borrel/a burgdorferi  as a membrane-assodated lipoprotein 
resuhed in protective antibody responses that were 100-1,000-fold higher than responses elicited 
by immunization with recombinant BCG expressing OspA cytoplasmicaUy or as a secreted fusion 
protein. Furthermore, these improved antibody responses were observed in heterogeneous mouse 
strains that vary in their immune responsiveness to OspA and sensitivity to BCG growth. Thus, 
expression of protective antigens as chimeric membrane-associated lipoproteins on recombinant 
BCG may resuh in the generation of new candidate vaccines against Lyme borreliosis and other 
human or veterinary diseases where humoral immunity is the protective response. 
(BCG) 1  attenuated  "~acille  Calmette-Guerin  an  bovine 
.13 tubercle bacillus used as a vaccine for tuberculosis, offers 
unique advantages for development as a multivalent vaccine 
vehicle for other human pathogens (1-5).  In initial studies 
recombinant BCG was shown to elicit both humoral and cel- 
lular responses to heterologous target antigens such as B-galac- 
tosidase, expressed cytoplasmicaUy as hsp60-lacZ gene fusions 
(1). Subsequent studies in this laboratory have further demon- 
strated cytoplasmic expression of numerous antigens in rBCG, 
but expression levels have proven to be highly variable from 
antigen to antigen, and humoral responses to some cytoplas- 
micaUy expressed antigens, including some antigens expressed 
1  Abbreviations used in this paper: BCG, bacille Calmette-Guerin;  OspA, 
outer surface protein A; RBS, ribosomal binding site; T, Tween; TX, 
Triton X. 
at  high levels (e.g.,  HIV  reverse  transcriptase),  have been 
difficult to achieve. Furthermore, humoral responses to most 
target antigens expressed in the cytoplasm of rBCG show 
substantial heterogeneity among different inbred mouse strains, 
and even within individuals of a single strain (our unpub- 
lished data). Therefore, approaches to increase the relative im- 
munogenicity of target antigens expressed at lower levels in 
rBCG were considered in an effort to enhance humoral re- 
sponses  elicited by rBCG.  Since abundant bacterial surface 
proteins are often highly immunogenic, other investigators 
developing Salmonella and Escherichia coli vaccine vehicles have 
targeted small antigens or epitopes to the bacterial surface 
by expression as fusion proteins with flagella,  fimbriae, or 
major  outer membrane protein  A  (OmpA)  and  •  phage 
receptor (LamB) (6-10). As comparable immunogenic pro- 
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mycobacteria, we have chosen to use signal peptides derived 
from  lipoproteins  (11) to  direct  export  and  membrane- 
associated surface expression of target antigens in BCG.  In 
addition to the potential for improved antigen presentation 
by surface expression on rBCG, lipid acylation can dramati- 
cally increase the ability of synthetic peptides (12, 13) to elicit 
immune responses.  Moreover, lipoproteins of bacterial patho- 
gens are highly immunogenic in vivo and some bacterial li- 
poproteins have been implicated as protective antigens (14-22). 
Possibly the most notable of promising protective bacterial 
lipoprotein antigens is the outer surface protein A  (OspA) 
antigen  of Borrelia burgdorferi, the causative agent of Lyme 
disease (23-25). A number of studies have implicated OspA 
as a protective antigen and OspA-specific antibodies as pro- 
tective against Lyme borreliosis in the mouse model (26-29). 
Passive transfer of monoclonal and polyclonal sera specific for 
OspA  was shown  to protect  mice against  challenge  with 
tg burgdoq'eri  (26, 27). Removal of antibodies specific for OspA 
greatly diminished  the protective component in polyclonal 
sera generated by immunization  with whole killed Borrelia 
(28).  Studies  using  non-lipid  acylated  OspA-glutathione 
S-transferase (OspA-GST) fusion protein in active immuni- 
zations have also demonstrated promising protection in the 
mouse model for Lyme borreliosis; however, protection re- 
quired repeated immunizations  with large doses of OspA- 
GST  and formulation  with  CFA,  which  is unsuitable  for 
human use (27-29). As a lipoprotein, OspA is insoluble and 
not expressed well in E. coli; accordingly, OspA can be un- 
wieldy  for  immunogenicity  studies  in  the  laboratory  or 
large-scale production  as a subunit vaccine (30).  Recently, 
however, it was demonstrated  that  purified OspA lipopro- 
tein (L-OspA) is profoundly more immunogenic than non- 
lipid acylated OspA (NL-OspA), even in the absence of adju- 
vant (31). Since OspA is a bacterial lipoprotein amenable to 
membrane translocation,  we used the ospA gene to test the 
function and utility of the rBCG lipoprotein expression vectors 
(LPE vectors) using mycobacterial lipoprotein signal peptides 
that  can enable the expression and export of heterologous 
chimeric lipoproteins  to the membrane of rBCG. 
In this study we report a comparison of immune responses 
elicited by immunization  with rBCG expressing the OspA 
antigen cytoplasmically, as a secreted fusion protein or as a 
membrane-associated lipoprotein. Immunization with rBCG 
expressing OspA as a chimeric lipoprotein, but not as a cyto- 
plasmic or secreted protein, resulted in high-titered antibody 
responses to OspA in all mouse strains tested, including out- 
bred mice. These OspA-specific antibodies inhibited growth 
of ~R burgdorferi in vitro and in vivo, and were protective in 
a mouse model for Lyme borreliosis. This study is a first test 
for a strategy to driver protective membrane-associated li- 
poproteins on live recombinant BCG vaccines, and has resulted 
in the development of a candidate vaccine against Lyme disease. 
Materials  and Methods 
Construction of BCG/E. coli Shuttle Expression Vectors  for Expres- 
sion of Ost~l.  All expression vectors described in this study are 
derivatives of plasmid pMV206 described by Stover et al. (1) and 
include DNA cassettes encoding kanamycin resistance, an E. coli 
origin of replication, a mycobacterial plasmid replicon derived from 
Mycobacteriumfortuitum  plasmid pAL5000, and a synthetic multiple 
cloning site (MCS). Plasmid pMV251 is a derivative of pMV261 
(1) with overlapping NcoI and BamHI restriction sites at the hsp60 
start codon. A DNA segment spanning the M. tuberculosis  (strain 
H37Rv) 19-kD  antigen  gene promoter,  ribosomal binding  site 
(RBS),  secretion signal, and the first six codons of the mature 
processed protein was amplified by PCR and cloned between the 
XbaI and BamHI sites of pMV206 to construct  plasmid p19PS. 
A DNA segment including  RBS and the structural  gene of the 
BCG ot antigen was amplified by PCR without the ct antigen stop 
codon and cloned between the XbaI and BamHI sites in the MCS 
of plasmid pRB26 (a derivative of pMV206 containing  the BCG 
hsp60 promoter)  to yield plasmid pAB26. An ospA gene segment 
encoding the ospA gene without the 5' region encoding the signal 
peptide (ospAA1-57) was amplified by PCR using oligonucleotides 
based on published sequence  data for/g burgdo~feri  strain B31 (35210; 
American Type Culture Collection  (Rockville, MD) OspA (25). 
These primers included a unique BamHI (5' OsloA primer) or SalI 
site (3' ospA primer) at their 5' ends to facilitate directional cloning. 
The resulting OspA PCR gene segment was digested with BamHI 
and SalI to generate cohesive ends at the 5' and 3' ends, respectively, 
and cloned in-frame between the BamHI and SalI sites of plasmids 
pMV261,  pAB26,  and p19PS to yield plasmids pMV261::ospA, 
pAB26::ospA, and p19PS::ospA. A complete ospA gene (including 
the signal region) was similarly constructed  with 5' NcoI site at 
the start codon and cloned between the NcoI and SalI sites of plasmid 
pMV251 to yield pMV251::ospA. 
Culture and Transformation  of BCG.  All liquid culture of BCG 
substrain Pasteur 1173 A2 was accomplished at 37~  in stationary 
tissue culture flasks (25 cm  2 with 5-10 ml or 75 cm  2 with 15-25 
ml) or roller bottles (490 cm  2 with 100-200 ml or 850 cm  2 with 
200-500 ml) with Dubos media (Difco Laboratories, Detroit, MI) 
supplemented with a 10% volume of albumin dextrose (AD) en- 
richment consisting of 5% BSA fraction V (Sigma Chemical Co., 
St. Louis, MO), 2% dextrose, and 0.85% sodium chloride. Liquid 
culture media included 0.02% Tween 80 (T80) to prevent clumping 
of BCG cells. BCG colonies were grown at 37~  on Middlebrook 
7H10 agar media (Difco Laboratories) supplemented  with  10% 
volume of AD enrichment. For transformation, BCG cultures were 
grown to densities of "~107 CFU/ml, sedimented at 4,000 g, and 
washed twice by resuspension and centrifugation  (4,000g) in 10% 
glycerol at 4~  and finally resuspended in 5% of the original cul- 
ture volume of cold 10% glycerol. 200 #1 of the cold BCG suspen- 
sion was mixed with plasmid DNA (50-500  ng) in a prechilled 
0.2-cm electroporation cuvette and transformed using a gene pulser 
electroporator  at 2.5 kV, 25/~f,  and 1,000 1] (Bio-Rad Laborato- 
ries, Richmond, CA). After electroporation,  50/~1 of 5 x  Dubos 
media was added to the BCG-DNA suspension and this mixture 
was incubated at 37~  for 1 h before plating on Middlebrook 7H10 
plates  supplemented  with  AD  enrichment  and  kanamycin  (15 
/~g/ml). 
Analysis of OspA Expression in rBCG.  BCG transformants were 
grown to mid-logarithmic phase in Dubos liquid media containing 
kanamycin (15/zg/ml),  sedimented at 4,000 g, and prepared for 
Western blot analysis by washing in a PBS +  0.05% TSO 20-fold 
concentration  by  centrifugation  and  sonication  in  radioim- 
munoprecipitation  assay (RIPA) buffer (1% NP-40, 0.5% deoxy- 
cholate, 0.1% SDS, 50 mM Tris (pH 8.0). Culture lysates approxi- 
mately equivalent to 5 x  106 bacteria were analyzed by SDS-PAGE 
and Western blot with the OspA-specific  mAb H5332 (18). Expres- 
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rived from strain B31 and to purified OspA lipoprotein, kindly 
provided by Dr. L. Erdile (Connaught Laboratories Inc., Swift- 
water,  PA).  Protein bands reacting with H5332 were visualized 
after incubation with a secondary antibody (goat anti-mouse IgG 
conjugated to horseradish peroxidase)  using the enhanced chemi- 
luminescent detection (ECL) system (Amersham Corp., Arlington 
Heights,  IL) according to manufacturers specifications. 
Localization of OspA Fusion Proteins in Recombinant BCG by Triton 
X-114 Phase Partitioning.  rBCG cells were sedimented from cul- 
tures, suspended in PBS, and cell suspensions were adjusted to equiva- 
lent densities.  Cells were disrupted by sonication and membranes 
were solubilized at 4~  by the addition of Triton X-114 (TX-114) 
to 2%  (vol/vol). Insoluble material (cell wall-enriched fraction) 
was sedimented by centrifugation at 100,000 g and the supema- 
rant was subjected to detergent phase partitioning (32). After briefly 
warming (37~  the TX-114 solutions, separation of aqueous and 
detergent phases was achieved by a short centtifugation. These two 
phases were back-extracted three times (33), and proteins in repre- 
sentative samples were precipitated by the addition of nine volumes 
of acetone. A portion of each culture supernatant was concentrated 
by ultrafiltration (Centricon 30; Amicon Corp., Danvers,  MA). 
Samples representing fivefold concentrated culture volume equiva- 
lents were subjected to SDS-PAGE,  transferred to nitrocellulose, 
and blotted with anti-OspA mAb H5332. Endogenous Hsp60, BCG 
o~ antigen (ccAg), and Mtb19 BCG homologous antigens were de- 
tected by Western blot with mAbs IT13, HYT27, and HYT6, 
respectively (kindly supplied by T. Shinnick, Centers for Disease 
Control, Atlanta, GA; and J. Ivanyi, Medical  Research  Council, 
Hammersmith Hospital, London, UK), as part of the United Na- 
tions Development Program/World Bank/World Health Organi- 
zation Special Programme for Research and Training in Tropical 
diseases. 
Surface Labeling and Flow Cytoraetry of rBCG Expressing OspA. 
Approximately 2  x  109 rBCG grown in Dubos-AD  were har- 
vested by centrifugation. The pelleted rBCG were washed with 
10 ml of PBS-T80 (pH 7.4),  resuspended in 5 ml PBS-T80, then 
fixed with an equal volume of 4% paraformaldehyde in PBS-T80 
for 10 rain at 4~  Fixed rBCG were pelleted and washed twice 
with 5 ml PBS-T80, then resuspended in a 1-ml volume of PBS- 
T80 for treatment with ot-OspA polyclonal sera. The anti-OspA 
polyclonal serum was generated by hyperimmunization of rabbits 
with purified OspA lipoprotein in IFA. Possible background reac- 
tivity was removed by exhaustive preadsorption with BCG lysate 
immobilized on nitrocellulose membranes. This preadsorbed anti- 
OspA polyclonal sera was added to the fixed rBCG cell suspension 
at a final dilution of 1:200 and incubated for 30 min at room tem- 
perature and 30 rain on ice. The rBCG were pelleted by centtifu- 
gation, washed twice with 0.5 ml PBS-T80, and resuspended in 
1 ml PBS-T80. Goat anti-rabbit FITC-conjugated secondary anti- 
body (GIBCO BRL, Gaithersburg, MD) was added to a final dilu- 
tion of 1:50 and incubated for 30 min on ice. The rBCG-antibody 
complex was pelleted by centrifugation, washed twice with I ml 
PBS-T80, and resuspended in 2 ml PBS-T80. Labeled rBCG were 
mildly sonicated to disperse clumped cells and dilutions were ana- 
e  @  lyzed by flow cytom try on a FACScan  (Becton Dickinson & Co., 
Mountain View,  CA). 
rBCG Preparation and Immunization.  rBCG cultures were grown 
to ODs of "~1.2 A~ U  (m2  x  10  s CFU/ml), concentrated 20- 
fold by sedimentation at 4,000g, and resuspended in 15% glycerol. 
1-ml vials of the rBCG glycerol suspension  were gradually frozen 
at a rate of -l~  from 4 to -40~  The frozen rBCG were 
stored at  -70~  until use. CFU were assayed by plating mildly 
sonicated dilutions of a thawed material on Middhbrook 7H10 plates 
+  kanamycin as described above. 
Female 4-6-wk-old BALB/c and C3H/HeJ inbred mice (The 
Jackson Laboratory, Bar Harbor, ME) and outbred Swiss Webster 
mice (Charles River Labs.,  Wilmington,  MA) were immunized 
(priming  and  boosting)  by  the  intraperitoneal  route  with  106 
rBCG CFU in  100/~1 of PBS-T80. 
Iramunogenicity of rBCG-oslx4 Constructs.  Sera were collected 
from the tail veins of immunized mice at 4-wk intervals and pooled 
for each group to monitor antibody responses  by ELISAs with 
R  burgdo!feri (strain B31) spirochetes.  ELISA plates  (Immulon 1) 
were coated with 50 #1 of whole Borrelia resuspended in 0.1  M 
carbonate buffer (pH 9.6) at 10 #g/ml protein or with 100 #1 of 
recombinant 0.1  ~g/ml OspA in the same carbonate buffer and 
incubated for 2-4 h at room temperature or overnight at 4~  The 
antigen  solution was  removed and plates  were incubated with 
blocking solution (0.5% BSA and 0.5% nonfat dry milk) in PBS 
with 0.1% Tween-20 (PBS-T20) for I h at room temperature. Two- 
fold serial dilutions of serum starting at 1:200 were made in blocking 
solution and 50 #1 of each dilution was added to duplicate wells 
of the antigen-coated plate. After an incubation at room tempera- 
ture for 1 h,  the coated plates  were washed with PBS-T20 and 
incubated with 50 #1 of a 1:1,000 PBS-T20 dilution of peroxidase- 
conjugated goat anti-mouse IgG (Kirkegaard & Perry Laborato- 
ries, Inc., Gaithersburg, MD) secondary antibody for 1 h. Color 
was developed with 2,2'-azino-di[3-ethyl-benzthiazoline sulfonate 
(6)] substrate reagent (Kirkegaard & Perry Laboratories,  Inc.) and 
measured by absorbance at 405 nm on an ELISA reader (Dynatech). 
Endpoint titers were defined as the highest dilution at which the 
A40s values were twice the values for preimmune sera diluted 1:200 
in blocking solution. 
Western immunoblot analysis was  performed with lysates of 
whole R  burgdorferi. After separation by SDS-PAGE and transfer 
to nitrocellulose, individual hnes were incubated for 1 h with pooled 
serum diluted 1:500 in PBS-T20, washed with PBS-T20, reacted 
with horseradish peroxidase-conjugated goat anti-mouse secondary 
antibody for 30 rain, and developed with the ECL chemilumines- 
cent substrate according to manufacturer's instructions (Amersham 
Corp.). 
In Vitro Growth Inhibition Assay.  In vitro growth inhibition an- 
tibody titers against the B31 strain of/~ burgdorferi  were determined 
as described elsewhere (34) for pooled sera from rBCG-immunized 
mice in two independent experiments. Wells  of a 96-we11, flat- 
bottomed microtiter plate were seeded with 2  x  106 spirochetes 
in 0.1 ml of BSK-II media derived from a late log-phase culture 
of a high-passage-number  isohte ofR burgdotferi  B31 (35210; Amer- 
ican Type Culture Collection) grown in the same medium. Before 
addition to wells mouse serum was heat inactivated (growth inhi- 
bition in this assay is complement independent) and filtered through 
a 0.22-#m filter to sterilize the serum. Twofold serial serum dilu- 
tions starting at 1:8 were added to duplicate culture wells in the 
96-well plates,  and the plates were sealed and incubated at 34~ 
for 72 h in a 1% CO2 atmosphere. Bacterial growth in each well 
was monitored by color changes in the phenol red indicator dye 
with a 580 ELISA reader at 490 nm (Dynatech Labs. Inc., Chan- 
tilly, VA). Spirochete growth was also confirmed by phase contrast 
microscopy in control wells. As a control for specificity of serum 
growth inhibition R hermsii strain HSI (35209; American Type Cul- 
ture Collection) was used in the same experiments. 
lg burgdorferi Challenge of  Mice Immunized with rBCG-OspA Vac- 
cines.  Challenge doses were derived by expansion of a single colony 
of the low-passage  R  burgdo!feri Sh.2  strain  (35)  and were ad- 
ministered 5 wk after the rBCG booster immunization. Immunized 
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spirochetes in experiment  1. In experiment  2, mice were inocu- 
lated intradermally  at the base of the tail with  104 spirochetes. 
This represented '~100 IDs0 units of the B. burgdorferi Sh.2 strain. 
Mice were killed 14 d after challenge, and plasma and bladder, heart, 
and joint tissues were harvested, minced, and cultured  in BSK-II 
media as described  previously (31). Cultures were monitored through 
day 14 by phase contrast microscopy for the presence of spirochetes. 
The presence of one or more spirochetes per 20 high-power fields 
in any one of the blood or tissue cultures was scored as a positive 
infection. 
Results 
Expression of  Membrane-associated OspA Lipoprotein on Recom- 
binant BCG.  Initial studies in this laboratory with an rBCG 
vaccine expressing OspA at high levels in the cytoplasm of 
rBCG resulted in modest anti-OspA humoral responses (36). 
We therefore initiated  strategies to express OspA as an ex- 
ported membrane-associated lipoprotein with the aim of en- 
hancing OspA immunogenicity in rBCG. Mice and humans 
immunized with BCG or infected with Mycobacterium tuber- 
culosis often exhibit  higher  titered  antibody responses to a 
19-kD antigen (Mtb19) than to the numerous other antigens 
of these mycobacteria (37,  38).  DNA  sequence analysis  of 
the  gene  encoding  the  immunogenic  Mtb19  antigen  of 
M. tuberculosis indicated that the hydrophobic NH2-terminal 
region was a lipoprotein signal peptide (39).  Subsequent bio- 
chemical analysis confirmed that the Mtb19 protein was lipid 
acylated by M. tuberculosis, presumably during the export pro- 
cess (40). Accordingly,  we constructed expression vectors using 
the Mtb19 lipoprotein signal peptide in an attempt to direct 
the expression,  export,  and lipid acylation of heterologous 
antigens, such as OspA, by recombinant BCG. For compar- 
ison,  an expression vector was also constructed for expres- 
sion  of fusion  proteins  with  the  olAg,  which  is  a 32-kD 
secreted protein  found in the culture filtrate BCG85 com- 
plex of BCG and other mycobacteria (41-45).  The c~Ag homo- 
logue ofM. kansasii has been used previously as a carrier pro- 
tein to secrete an HIV-1 Gag peptide from rBCG, but immune 
responses using this strategy have not been reported (44, 45). 
As a bacterial lipoprotein with promising vaccine ef~cacy, 
OspA was chosen as an appropriate antigen to test the utility 
of the rBCG lipoprotein  expression vectors (LPE vectors). 
With the aim of comparing immune responses to rBCG ex- 
pressing OspA as a cytoplasmic protein (C-OspA), a secreted 
protein  (S-OspA),  or as a membrane-associated lipoprotein 
(L-OspA),  we cloned an ospA gene segment excluding  the 
5'  signal peptide region  (OspA A1-18)  into  rBCG expres- 
sion vectors pMV261, pAB26, and p19PS,  respectively (Fig. 
1). A complete ospA gene segment including its native signal 
peptide was also cloned into rBCG expression vector pMV251 
in an attempt to derive expression of a complete and authentic 
OspA lipoprotein in rBCG (Fig.  1). Recombinant gene prod- 
ucts that were reactive with a mAb specific  for OspA were 
obtained at the predicted molecular weights for all ospA con- 
structs described above (Fig. 2). Expression levels of the OspA 
protein from the rBCG-pMV261::ospA construct were esti- 
mated  to  be  in  excess  of 10%  total  rBCG  protein  ('~20 
Promotor  Secretion  Sional  Antioen  Gene 
pMV261::ospA  ~~n~o  =  =  i n  n  n  a  t a  n  n  ~  11 n 
(C-OspA) 
pMV251::ospA ~----~-.~ 
(L-OspA) 
p19PS::ospA ~ 
(L19-OspA) 
pAB26::ospA ~~i~~1~L~ 
(S-O~oA) 
hsp60  m  BCG "heat shock" gene 
ospA  ~  Borrelia  burgdorferi  lipoprotein  gene 
mtb 19  ~  M. tuberculosis  lipoprotein  gene 
c(-ag  ~  secreted mycobacterial  protein gene 
Figure  1.  BCG/E.  coli shuttle expression  vectors  used to express  ospA. 
ng/106 rBCG),  while expression levels for OspA fusions to 
the Mtb19 signal peptide, the c~Ag, or the native OspA signal 
peptide were substantially lower ('~1-5 ng/106 rBCG).  Sur- 
prisingly,  chimeric  OspA lipoproteins  and the o~Ag-OspA 
fusion protein were seemingly more reactive in Western blot 
analyses  with  the OspA-specific H5332 mAb even though 
these gene products were expressed at much lower levels than 
the fusion protein expressed by pMV261::ospA (Fig. 2). This 
observation is probably explained by increased avidity of the 
o~Ag-OspA fusion protein and lipid acylated OspA lipopro- 
tein for the nitrocellulose membrane, as described in a previous 
study (30), since nonlipid acylated OspA has been shown to 
be antigenically  equivalent  to  OspA lipoprotein  (31). 
Figure 2.  Expression  of ospA in rBCG. Plasmids  constructed  in E. coli 
as described  in Fig. I were  transformed  into BCG substrain  Pasteur 1173A2 
by electroporation. Transformants were grown and '~5  x  106 rBCG bac- 
teria were harvested and analyzed by SDS-PAGE (top) and Western blot 
with OspA-specific  mAb H5332  (bottom) for comparison  to a/~ burgdorferi 
lysate, and purified OspA lipoprotein. 
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by TX-114 phase partitioning,  rBCG lysates were ffactionated by centrifuga- 
tion and TX-114  phase  partitioning as described in Methods.  Samples 
representing fivefold concentrated culture volume equivalents  were sub- 
jected to SDS-PAGE, electroblotted to nitrocellulose, and reacted with anti- 
OspA mAb H5332 (left). Identically  processed fractions from nonrecom- 
binant BCG were blotted with appropriate mAbs specific for the BCG 
orM. tuberru/a~ hsp60 (IT13), o~-Ag  (HYT27), or Mtb19 antigens (HYT6) 
to determine the cellular location of the endogenous fusion partners. Lane 
W, whole cell sonicate;  lane I, TX-114-insoluble  material (cell wall en- 
riched); lane/1, aqueous phase (cytosol enriched); lane D, detergent phase 
(membrane/lipoprotein enriched);  lane M, fivefold concentrated culture 
medium (secreted).  Positions of chimeric OspA protein hands are indi- 
cated by arrows at 31 kD. Positions of the endogenous BCG proteins used 
as fusion  partners are indicated on the right with the molecular masses 
(in kD). 
To determine if expression of ospA genes from the lipo- 
protein expression vectors actually resulted in export and lipid 
acylation of recombinant OspA, exponentially growing cul- 
tures of the rBCG-OspA recombinants and nonrecombinant 
BCG were subjected to cell fractionation  and TX-114 deter- 
gent phase partitioning analysis to  enrich for membrane- 
associated lipoproteins (32, 33). The OspA gene product en- 
coded by pMV261::ospA (C-OspA) was found exclusively in 
the aqueous cytosolic  fraction and correlated with the restricted 
cytoplasmic  location of the BCG Hsp60 (Fig. 3). The o.Ag-ospA 
gene product (S-OspA) expressed by plasmid pAB26::ospA 
as well as the endogenous BCG c~Ag were found in the in- 
soluble  cell wall-enriched fraction,  aqueous cytosolic frac- 
tion,  and the extraceUular media fraction,  but  not in the 
detergent-soluble membrane-enriched fraction. The presence 
of the otAg-OspA fusion protein or ccAg in the rBCG cul- 
ture media was not due to rBCG autolysis inasmuch as hsp60, 
which we determined to be exclusively cytosolic in exponen- 
tially growing cultures, was not found in the culture media. 
Compared with the native BCG nAg, a smaller fraction of 
the total S-OspA fusion protein pool was secreted into the 
media, while a larger portion was found in the cell wall-en- 
riched insoluble  fraction.  This suggested  that some of the 
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exported ocAg fusion protein associated with the cell wall, 
although the possibility that some of the c~Ag-OspA is ex- 
pressed as an insoluble cytoplasmic inclusion can not be ex- 
cluded by these data. Substitution of the Mtb19 signal pep- 
tide for the OspA  signal peptide resulted  in expression of 
a chimeric OspA (L19-OspA) that was almost exclusively lo- 
cated in the detergent-soluble  fraction,  which is highly en- 
riched for lipophilic proteins.  This finding correlated with 
the location of the endogenous membrane-associated Mtb19 
lipoprotein BCG homologue and indicated that fusion of the 
Mtb19 signal peptide to OspA did indeed direct efficient ex- 
port and posttranslational  modification of the chimeric L19- 
OspA  protein to the membrane of rBCG.  This result was 
in contrast to the predominantly cytosolic location for the 
gene product encoded by pMV251::ospA (L-OspA),  where 
a very minimal amount of OspA was found in the detergent- 
soluble lipophilic  fraction.  This result was possibly indica- 
tive of inefficient or incomplete processing  of the foreign 
Borrel/a signal peptide by the my~obacterial  lipoprotein-specific 
signal peptidase  II. 
The rBCC-OspA bacilli were also analyzed by flow cytom- 
etry to confirm predictions of the cellular localization of the 
recombinant OspA gene products (Fig. 4). rBCG expressing 
L19-OspA, L-OspA, and S-OspA, from plasmids p19PS::osFA, 
pMV251::ospA, and pAB26::ospA, respectively, all demon- 
strated increased  surface  fluorescence  with anti-OspA sera when 
compared with nonrecombinant BCG or rBCG expressing 
C-OspA from plasmid pMV261::ospA. Although discernibly 
less than that of rBCG expressing L19-OspA,  the surface 
fluorescence  exhibited by rBCG with plasmid pMV251::ospA 
was somewhat surprising  in light of the finding that  the 
majority of this OspA protein was cytosolic. Nevertheless, 
this finding was in general agreement with the TX-114 ffac- 
tionation analysis, which indicated that a small amount of 
lipophilic L-OspA was associated with the BCG membrane 
as a lipophilic protein. The rBCG expressing the S-OspA from 
vector pAB26::ospA also exhibited surface fluorescence, thus 
confirming the finding that the oLAg-OspA fusion protein 
found in the TX-114-insoluble fraction was cell wall associated 
and not derived primarily from insoluble cytoplasmic inclu- 
sion bodies. Further confirmation of OspA surface localiza- 
tion by fusion to the Mtb19 lipoprotein signal peptide or c~Ag 
in rBCG was obtained  by immunoelectron microscopy  of 
rBCG thin sections (data not shown, S. Hanson et al., manu- 
script in preparation).  These data,  taken together with the 
fractionation and TX-114 phase partitioning analysis, confirm 
that it is possible to export OspA to the exterior of rBCG 
as a chimeric membrane-associated lipoprotein by fusion to 
the Mtb19 lipoprotein signal or as a secreted and cell wall-as- 
sociated protein by fusion  to the c~Ag. 
Enhanced Humoral Response to rBCG Membrane-associated 
OspA.  A survey of 24 inbred and outbred mouse strains was 
performed to determine relative humoral responsiveness to 
recombinant OspA expressed in the cytoplasm ofrBCG and 
to determine whether the mouse BCG allele, which confers 
resistance or sensitivity to in vivo growth of BCG and other 
intracellular pathogens, had any impact on responsiveness to 
rBCG-expressed OspA (46). OspA-specific  antibody responses -0 
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Figure  4.  Surface labeling and 
flow cytorrletry  of rBCG expressing 
OspA. rBCG containing the desig- 
nated plasmids and expressing the 
designated  chimeric OspA gene 
products (shaded histograms) are com- 
pared  to  nonrecombinant BCG 
(open histograms). 
resulting from immunization with rBCG pMV261::ospA ex- 
pressing C-OspA did not correlate with the mouse BCG al- 
lele, as responding mouse strains carrying either BCG-s (sen- 
sitive)  and  BCG-r  (resistant)  alleles  were  observed  (46). 
C3H/He, BALB/c, and outbred Swiss Webster mice responded 
to rBCG-pMV261::ospA immunization with high (not re- 
quiring boosting), intermediate (requiring boosting), and low 
(barely detectable after boosting) anti-OspA responses, respec- 
tively. In addition to their variable responses to OspA, these 
mouse strains  differ with respect to their resistance to BCG 
growth; BALB/c mice carry the BCG-s (sensitive) allele and 
both C3H and outbred Swiss Webster mice are BCG-r (resis- 
tant).  Thus,  these three mouse strains  provided a manage- 
able representative sampling of mouse phenotypes for com- 
parison of rBCG vaccines expressing OspA as a cytoplasmic 
protein, a membrane-associated  lipoprotein, or as a cell wall-as- 
sociated and secreted protein.  C3H/HeJ,  BALB/c,  and the 
outbred Swiss Webster mice were immunized intraperitoneaUy 
with  106 CFU  of rBCG-OspA  and pooled  sera were  ana- 
lyzed by ELISA to whole Borrelia at 4, 8, 12, and 16 wk after 
a single immunization. All mice were boosted at 17 wk with 
the same rBCG vaccine used in the initial immunization and 
sera were analyzed for reactivity to OspA 2 wk postboost. 
All three mouse strains immunized with rBCG vaccines ex- 
pressing OspA as lipoproteins (L-OspA and L19-OspA) ex- 
hibited strong OspA-specific antibody responses within 4-8 
wk after  a single rBCG-OspA  immunization,  as measured 
by ELISA to whole Borrelia (Fig. 5). Similar responses to rBCG 
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Figure  5.  Comparison of  im- 
munogenicity of rBCG-ospA con- 
structs (cytoplasmic, secreted, and 
lipid acylated). Mouse strains were 
immunized by the intraperitoneal 
route with 10  6 CFU of rBCG and 
boosted at 17 wk with the identical 
dose. Sera were collected at the in- 
dicated times, pooled, and analyzed 
by ELISA  with whole B~ burgdorferi 
(strain B31). 
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rBCG  vector* 
immunogen 
Mean anti-OspA endpoint titer* 
mouse serum (2 wk postboost) 
BALB  C3H  Swiss 
pMV261::ospA  400  +_ 0  400  +_ 0  400  + 0 
(C-OspA) 
pMV251::ospA  289,631  _+  58,341  243,550  _+  42,415  204,800  _+  0 
(L-OspA) 
p19PS::ospA  243,550  _+  42,415  819,200  _+  0  43,054  _+  7,498 
(L19-OspA) 
pAB26::ospA  2,691  _+  469  12,800  _+  0  951  _+  166 
(S-OspA) 
BCG controls  400  _+  0  200  _+  0  400  _+  0 
* Vector  used to express OspA gene in rBCG vaccine. 
ELISA to purified OspA lipoprotein. 
S Nonrecombinant BCG (Pasteur  substrain). 
C-OspA  were  not  seen  until  after  boosting.  Particularly 
striking were the anti-OspA responses  elicited  by a single 
dose of either of the rBCG-L-OspA vaccines in the low re- 
sponder outbred Swiss Webster mice. This mouse strain im- 
munized with rBCG expressing OspA as a cytoplasmic or 
secreted protein did not mount anti-OspA responses even after 
boosting. Peak anti-OspA antibody titers >1:10  s in BALB/c 
and  C3H  mice and  1:104 in  Swiss  mice were elicited  by 
boosting with rBCG-L-OspA constructs. These responses 
were 100-1,000-fold  higher than the responses induced with 
rBCG constructs expressing as a cytoplasmic protein or secreted 
surface-associated OspA-ctAg fusion protein. The specificity 
of antibodies (pooled sera) to OspA generated by immuniza- 
tion with rBCG-OspA vaccines  was confirmed  by ELISA with 
purified OspA lipoprotein (Table 1) and Western blot anal- 
ysis with R  burgdorferi lysates (Fig. 6). Analysis of individual 
mouse anti-OspA titers revealed that all mice immunized  with 
rBCG-L-OspA vaccines responded comparably, while signi- 
ficant  individual mouse-mouse variation was  observed in 
animals immunized with rBCG vaccines expressing C-OspA 
or S-OspA (data  not shown). 
Protection against li burgdo~'eri  Infection with an rBCG-based 
Vaccine.  The OspA antigen ofR burgdorferi has been shown 
to be protective in both immunocompetent  and immunode- 
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Figure 6.  Western  blot  reac- 
tivity  of  antibodies  elicited  by 
rBCG-OspA vaccines.  A R burgdor. 
fen' lysate (strain B31) was reacted 
with pooled immune sera collected 
2 wk after a single booster immu- 
nization  from  rBCG-immunized 
BALB/C, C3H/HeJ, or Swiss Web- 
ster mice. Pooled immune sera was 
derived from mice immunized  with 
rBCG  expressing  OspA  from 
vectors  pMV261::ospA (C-OspA, 
lanes  1),  pAB26::ospA (S-OspA, 
lanes 2),  plgPS::ospA (L19-OspA, 
lanes 3),  pMV251::ospA (bOspA, 
hnes 4), from mice immunized with 
control  nonrecombinant  rBCG 
(BCG  Pasteur, lanes 5),  or  from 
mice  bled  before  immunization 
(pt~immune sen, lane 6). Identical 
R burgdorfer/lysates  were also reacted 
with  OspA-specific mAb  H5332 
(lane M) and anti-OspA hyperim- 
mune rabbit sera (lane P). Table  2.  In  Vitro  Growth Inhibition  Titers and In  Vivo Protection against B.  burgdo!feri Challenge (Exp.  I) 
In vitro growth 
inhibition  titer*  of 
mouse serum 
In vivo protection:  no.  mice with culturable 
borrelia in  tissues or blood/total  no.  mice* 
Bladder culture  Heart culture 
rBCG vector  s 
immunogen  BALB  C3H  BALB  C3H  BALB  C3H 
pMV261: :ospA  <8  32  5/5  3/4  1/5  0/5 
(C-Osp^) 
pMV251::ospA  4,096  1,024  0/5  0/5  0/5  0/5 
(L-OspA) 
p19PS: :ospA  1,024  2,048  0/5  3/5  0/5  0/5 
(L19-OspA) 
pAB261::ospA  ND  256  4/5  3/5  1/5  1/5 
(S-OspA) 
BCG control II  <8  <8  4/4  5/5  3/4  3/5 
B. burgdorferi challenge used 106 CFU of low-passage SH.2  strain (31, 35). 
* Number of mice in each group testing positive for borrelia infection (low-passage Sh.2 strain) by culture of tissues 14 d after challenge as a fraction 
of the total number of mice per group (31). 
* Reciprocal of the highest  dilution of mouse serum at which borrelia growth is inhibited in culture  (34). 
S Vector used to express OspA gene in rBCG vaccine. 
Ir Nonrecombinant  BCG (Pasteur substrain). 
ficient mouse models for Lyme borreliosis,  and this protec- 
tion has been shown to be antibody mediated (27-29).  Im- 
mune sera collected 2  wk after a single booster immuniza- 
tion of C3H and BALB/c mice immunized with the different 
rBCG-OspA vaccines were analyzed for their ability to in- 
hibit growth of the cuhure-adapted B31 laboratory strain of 
B~ burgdorferi in vitro (34). Antisera derived from immuniza- 
tions with both rBCG-L-OspA vaccines (rBCG-p19PS::ospA, 
rBCG-pMV251::ospA)  exhibited  high-titered/~  burgdorferi 
growth-inhibiting  activity,  while  sera  derived  from  mice 
immunized  with  the  rBCG-C-OspA  vaccine  (rBCG- 
pMV261::ospA)  or nonrecombinant BCG showed low or un- 
detectable growth-inhibiting titers (Table 2). In identical assays, 
immune  sera from rBCG-OspA-immunized  mice failed to 
inhibit the growth of/g hermsii,  which does not express OspA 
(data not shown). This demonstrated that growth inhibition 
was OspA specific and not due to a nonspecific mode of ac- 
tion  against borrelias. 
Based on these results, C3H and BALB/c mice were chal- 
lenged intraperitoneaUy with 106 borrelia spirochetes derived 
from an infectious clone of the low-passage Sh.2  strain  of 
13, burgdorferi (35) of the same OspA serogroup as B31 (47). 
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Figure 7.  Immunogenicity  of 
rBCG bospA constructs. The indi- 
cated  mouse  strains were  im- 
munized by the intraperitoneal route 
with  106  CFU  of the  indicated 
rBCG and boosted at 17 wk with 
an identical dose. Sera  were collected 
at  the  indicated times from each 
,~-~ o  ~"  ~  o  ~-~  ~v  ''~ o  ~-~"  group (five  mice), pooled, and ana- 
l  I  I  I  I__l  lyzed by ELISA  with whole/~ burg. 
pMVZ61 ::gp41  pMV2Sl ::ospA  pl 9PS:ospA  d~ct1'  (.4) and in the in vitro growth 
(neg, control)  (L-OspA)  (L19-OspA)  inhibition  assay  (B) (34). 
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lg burgdogCeri  growth in vivo was assayed  by culture of  bladder 
and heart tissues taken from mice 2 wk after challenge, the 
normal peak of spirochetemia in a borrelia-infected mouse. 
All mice immunized with an irrelevant BCG control were 
found to be infected, as determined by positive borrelia cul- 
ture from bladder tissue. Heart cultures appeared to be a less- 
sensitive indication of infection in these control mice. Three 
of four groups of mice immunized with rBCG-OspA lipo- 
protein vaccines  were completely protected from intraperitoneal 
challenge with 106 spirochetes, as determined by bladder cul- 
ture of  borrelia (Table 2). Evidence of borrelia breakthrough 
was observed with this high-challenge dose in one group of 
C3H mice immunized with the rBCG-p19PS vaccine despite 
substantial neutralizing antibody titers. However, this rBCG 
L-OspA vaccine completely protected BALB/c mice. In con- 
trast,  immunization with rBCG vaccines expressing OspA 
as a cytoplasmic protein, or as a secreted/cell wall-associated 
protein, resulted in incomplete protection against challenge. 
Some reduction in culturable borrelia from heart tissue was 
observed, but no significant differences were found in the 
culture of the bladder tissues compared with control BCG- 
immunized mice (Table 2). 
It has been shown that the intradermal route of borrelia 
challenge is more efficient for establishing infection in mice 
and is presumably more relevant to an infection delivered by 
a tick bite (48). Therefore, in a second experiment we deter- 
mined whether the rBCG-L-OspA vaccines eliciting  the 
highest antibody titers and protective responses against in- 
traperitoneal  borrelia challenge (rBCG-pMV251::ospA  and 
rBCG-plgPS::ospA) could similarly protect mice against in- 
traderrnal challenge.  As in the first experiment, C3H, BALB/c, 
and Swiss mice were immunized intraperitoneaUy with 106 
CFU of each rBCG vaccine, and boosted at 17 wk. All three 
strains of mice immunized  with rBCG-L-OspA vaccines  again 
exhibited high OspA-specific antibody titers before and after 
boost, while mice immunized and boosted with an irrele- 
vant BCG control did not (Fig. 7 A). Immune sera  collected 
from C3H and BALB/c mice 8 wk after the primary immu- 
nization with rBCG-L-OspA vaccines exhibited substantial 
growth-inhibiting antibody titers (1:500-1,000), while sera 
from all three mouse strains collected 2 wk postboost  ex- 
hibited higher growth-inhibiting antibody titers (Fig. 7 B). 
All immunization groups were challenged intradermally 4 
wk postboost with 104 borrelia, and plasma, bladder tissue, 
and tibiotarsal joints were cultured for detection of borrelia 
infection  14 d postchallenge. Both rBCG-L-OspA vaccines 
completely protected all three mouse strains against intradermal 
challenge; spirochetes could not be cultured from any of the 
tissues or plasma tested (Table 3). In contrast, all mice im- 
munized with a control irrelevant recombinant BCG were 
shown to be infected, as indicated by the positive culture of 
t?, burgdolferi  spirochetes from either plasma, bladder, or  joint 
tissues.  The  104  borrelia  challenge  dose  used  in  this  in- 
tradermal challenge experiment is roughly estimated to be 
comparable to an infection from 5-50 infected flat nymphal 
stage ticks (Ixodes dammini) (49). 
Discussion 
Significant progress has been made toward the identification 
of protective antigens for a wide variety of diseases but basic 
difficulties central to practical vaccine development still exist. 
Among the most formidable obstacles is the cost-effective 
production of immunogenic vaccine components in suffident 
quantities for wide use and the ddive,'y of these components 
Table  3.  Protection against Intradermal Challenge with B.  burgdorferi (Exp. 2) 
In vivo protection:* no. mice with culturable borrelia in tissues or blood/total no. mice 
Bladder culture  Blood culture  Joint culture  Total culture positive* 
rBCG vector  s 
immunogen  BALB  C3H  Swiss  BALB  C3H  Swiss  BALB  C3H  Swiss  BALB  C3H  Swiss 
pMV251::ospA  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5 
(L-OspA) 
p19PS::ospA  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5 
(L19-OspA) 
pMV261::gp411r  4/4  4/5  2/5  4/4  4/5  4/4  3/4  4/5  2/4  4/4  5/5  4/4 
(rBCG control) 
100 LDs0 (104 spirochetes) of low-passage Sh.2 strain (31, 35). 
* Number of mice in each group testing positive for borrelia infection by culture of tissues 14 d after challenge as a fraction of the total number 
of mice per group (31). 
* Number of mice culture positive for any single tissue or blood culture. 
S Vector  used to express OspA gene in rBCG vaccine. 
II rBCG expressing HIV-1 gp41 in expression vector  pMV261  (1). 
205  Stover et al. in a safe and immunogenic  form. One approach taken to over- 
come vaccine production and delivery problems is the devel- 
opment of live attenuated vaccines that replicate and express 
protective antigens in vivo. With the development of recom- 
binant DNA methodology has come approaches to modify 
live attenuated vaccines, (e.g., pox viruses and Salmonella) to 
produce heterologous antigens protective against a variety 
of diseases. As a widely used human vaccine against tubercu- 
losis, the live attenuated BCG vaccine also offers consider- 
able advantages for development as a multivalent vaccine ve- 
hicle  for  other  human  pathogens  (4).  With  the  recent 
development of genetic vector systems for the slow-growing 
mycobacteria, it is now possible to evaluate the potential for 
recombinant BCG as a multivalent live carrier for inducing 
protective immunity to heterologous antigens (1-5). 
Inasmuch as BCG is rapidly ingested by macrophages and 
grows within the macrophage phagolysosome, rBCG is usu- 
ally thought of as a vaccine vehicle for eliciting stronger cel- 
lular responses than humoral responses. Initial studies with 
model rBCG vaccines expressing E. coli fl-galactosidase indi- 
cated that substantial cellular and humoral responses to target 
antigens delivered as rBCG cytoplasmic proteins were pos- 
sible (1). Subsequent follow-up studies with a number of target 
antigens expressed in the cytoplasm of rBCG have indicated, 
however, that primary target antigen-specific antibody re- 
sponses in mice are generally more difficult to obtain or are 
highly variable and strain specific. To improve the potential 
of recombinant BCG vaccines to elicit protective humoral 
responses to target antigens, we have developed expression 
vectors using signal sequences derived from mycobacterial li- 
poproteins to direct the export of recombinant target antigens 
to the membrane of the BCG carrier  as immunogenic chi- 
meric lipoproteins. This strategy was based on the reasoning 
that bacterial  lipoproteins are membrane associated,  some- 
times located at the surface of the bacterium, and are often 
among the most immunogenic antigens recognized by the 
infected host's humoral immune response (15-22). In the case 
of M. tuberculosis, at least two lipoproteins, the 19- and 38- 
kD (Mtb19 and Mtb38) antigens, are among the most im- 
munogenic of antigens recognized by infected humans (37, 
38).  While the immunogenic nature of some lipoproteins 
may be  due in  part  to  their location in  the  membranes 
of bacteria, evidence is mounting that the inherent immuno- 
genicity of lipoproteins is due in large part to the NH2-ter- 
minal lipid moiety. This has now been directly demonstrated 
for OspA (31, and this study). Furthermore, chemical lipid 
acylation of peptides and proteins can profoundly enhance 
their immunogenicity (12, 13). A definitive explanation for 
this widely observed augmentation ofimmunogenicity  is not 
yet available, but as free lipoproteins or lipopeptides, it might 
be possible that the NH2-terminal lipid moieties might as- 
sociate as micelles, which could be more readily taken up by 
APCs. This could then enhance antigen presentation to T 
cells, which could in turn result in improved T help for cyto- 
toxic cellular responses and B cell humoral responses. While 
this explanation might be tenable for subunit vaccines it does 
not explain  why a lipoprotein expressed on rBCG, which 
is readily taken up by APCs, might be more immunogenic 
than the same antigen expressed in the cytoplasm of BCG. 
It is perhaps possible that exterior lipoproteins of rBCG are 
shed and are therefore more rapidly available to antigen pro- 
cessing mechanisms in the macrophage phagolysosome than 
are BCG cytoplasmic proteins. It might also be possible that 
L-OspA expressed on the surface of rBCG can directly prime 
B cells when BCG are extracellular, resulting in a synergistic 
response that normally does not occur to the same antigen 
expressed in the cytoplasm of BCG. Yet other explanations 
might be based on alternative  antigen processing pathways 
for lipoproteins or the possibility that some lipoproteins or 
lipopeptides are mitogenic (12, 14). It should be noted, how- 
ever, that enhanced humoral immune responses to BCG an- 
tigens were not observed in mice immunized with rBCG 
L-OspA vaccines (data not shown), arguing against the pos- 
sibility that L-OspA expression in rBCG is somehow mito- 
genic. The elucidation of the mechanism by which lipid acy- 
lation enhances OspA reactivity requires further study. Such 
studies should include a comparison of T  cell responses to 
OspA and additional antigens expressed cytoplasmically or 
extracellularly  as lipoproteins or secreted proteins. 
The insoluble nature of lipoproteins makes them gener- 
ally more di~cult to evaluate as candidate vaccines (e.g., OspA; 
30). It is also likely that some lipoproteins require membrane 
association to exhibit authentic conformational epitopes. The 
expression of target lipoprotein antigens in rBCG obviates 
the need to purify the membrane-bound and insoluble lipo- 
proteins, and presents the opportunity to express these an- 
tigens in a more authentic membrane-associated context. In 
addition to the delivery of natural lipoproteins by rBCG, it 
may be possible  to enhance the immunogenicity of non- 
lipoprotein antigens by making them chimeric lipoproteins 
fused to mycobacterial  signal peptides.  While many target 
antigens will be refractory  to export and lipid acylation by 
rBCG, additional studies in this laboratory indicate that some 
nonlipoprotein antigens can also be exported and lipid modified 
with the Mtb19 and Mtb38 lipoprotein (50) signal sequences 
using the same LPE vectors described in this study (e.g., PspA 
of Streptococcus pneurnoniae; Stover et al., manuscript in prep- 
aration).  Studies are in progress to determine whether the 
immunogenicity  of nonlipoprotein target antigens can be en- 
hanced by rBCG delivery as chimeric membrane-associated 
lipoproteins.  In comparison with other approaches involving 
the grafting of epitopes into bacterial cell surface structures, 
the chimeric lipoprotein approach used in this study has sev- 
eral advantages: (a) only minimal sequence information may 
be necessary to direct export of recombinant target antigens; 
(b) the signal peptide directing export is ultimately removed, 
minimizing contextual effects on important antigenic deter- 
minants; and (c) the target antigen is membrane anchored 
by means of an NH2-terminal lipid moiety that may enhance 
immunogenicity  (11-14). Since BCG has a single membrane, 
it may also be generally easier to export foreign antigens from 
rBCG than it is in Gram-negative bacterial  vector systems 
with inner and outer membranes separated by a periplasmic 
space. 
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rBCG vaccines expressing OspA as a lipoprotein were supe- 
rior to rBCG vaccines that express OspA in their cytoplasm 
or as a secreted/surface  protein associated,  at least in part, 
with the BCG cell wall.  rBCG-OspA lipoprotein vaccines 
elicited earlier, higher titered, protective anti-OspA responses 
that were consistent from mouse to mouse. These protective 
humoral responses were also induced in mice that are lower 
responders to OspA. The comparison of anti-OspA responses 
generated by rBCG expressing L-OspA and L19-OspA with 
the responses generated by rBCG expressing secreted surface- 
expressed S-OspA suggests that lipid acylation of OspA may 
have a greater impact on the potential to generate humoral 
responses  to OspA than surface expression by BCG. How- 
ever, a strict comparison is not possible with these data as 
it was necessary to fuse OspA to a full-length secreted pro- 
tein (c~Ag) to obtain a secreted/cell  wall-associated fusion 
protein. It is of interest that rBCG expressing potentially 
authentic OspA polypeptide encoded by plasmid pMV251::ospA 
exhibited surface fluorescence and elicited a high-titered and 
protective anti-OspA response even though only a very small 
amount of the protein appears to be authentically processed 
(lipid-modified L-OspA) in comparison with rBCG vaccine 
expressing L19-OspA from plgPS::ospA. This may occur be- 
cause the borrelia OspA signal peptide is sufficiently dissimilar 
from that recognized by mycobacterial  acylation  enzymes, 
so that this lipid modification, a prerequisite for signal pepti- 
dase  II-mediated  export,  occurs  very  inefficiently.  The 
nonacylated OspA might then be exported by the major signal 
peptidase I-mediated pathway.  However,  this explanation 
would also require OspA to be anchored to the exterior of 
BCG in the absence of lipid modification (OspA protein was 
never found in rBCG-pMV251::OspA culture supernatants) 
and would also suggest that BCG surface-expressed nonlipid 
acylated OspA is very immunogenic. These explanations seem 
unlikely in light of the recent evidence that purified free OspA 
lipoprotein is profoundly more immunogenic than nonlipid 
acylated OspA (31). Rather, it is more likely that the BCG- 
pMV251::OspA vaccine is very effective because only a very 
small amount of L-OspA in the context of rBCG is actually 
necessary to achieve enhanced anti-OspA immune responses. 
This small amount of authentic L-OspA expressed in rBCG- 
pMV251::osivA may be more immunogenic per molecule 
equivalent simply because it is more authentic than the lipid- 
modified chimeric L19-OspA, which carries an additional five 
amino acid residues from the Mtb19 lipoprotein as its NH2 
terminus. It is also of interest that rBCG expressing OspA 
as a membrane-associated lipoprotein are attenuated in their 
ability to replicate and persist in vivo as compared with non- 
recombinant BCG (data not shown). This is in contrast to 
what one would expect for a live vaccine, which elicits en- 
hanced target antigen-specific immune responses. The effect 
of this attenuation on the ability of the rBCG vaccine to elicit 
cell-mediated immunity and to protect against M. tuberculosis 
challenge is currently under investigation in the mouse model. 
Although comparisons between immune responses elicited 
by OspA lipoprotein subunit vaccines with live rBCG-OspA 
vaccines were not the aim of this study, comparisons with 
a recently published study on a purified L-OspA subunit vac- 
cine (31) suggest advantages for the delivery of OspA lipo- 
protein by rBCG. Comparison of growth inhibition titers 
obtained from both studies is possible  as these titers were 
obtained from the same mouse strain sera (BALB/c and C3H) 
by identical assays in the same laboratory (Sadziene, A., un- 
published data). Primary immunization and boosting of C3H 
mice and BALB/c mice with the highest doses tested (10 and 
2.5/~g, respectively) resulted in maximum growth inhibi- 
tion titers of 1:1,024 and 1:512 in the previous study on the 
L-OspA subunit vaccine (31). In experiment 1 of the present 
study, immunization and boosting of the same mouse strains 
with either rBCG L-OspA vaccine resulted in borrelia growth- 
inhibiting titers ranging from 1:1,024 to  1:4,096.  Higher 
growth-inhibiting titers (1:8,924-32,768)  were obtained in 
C3H and BALB/c mice in experiment 2. Moreover, immu- 
nization of three different mouse strains with a single dose 
of rBCG L-OspA and L19-OspA vaccines resulted in sub- 
stantial  anti-OspA titers ranging from 1:103 in the outbred 
Swiss  Webster  mouse to  1:104 in  the  inbred  C3H  and 
BALB/c mice. These primary responses, which lasted in >16 
wk, resulted from immunization with a rBCG inocula of 
104 CFU that initially contained only 1-5 ng of L-OspA. 
In the previous study, immunization with 10 #g of purified 
L-OspA (200-1,000-fold more L-OspA than delivered in the 
initial rBCG L-OspA inoculum) elicited very weak but de- 
tectable primary responses in the more OspA-responsive C3H 
mice, while primary responses in the less OspA-responsive 
BALB/c mice were not reported (31). These observations sug- 
gest the enhancement of OspA immunogenicity  by delivery 
as a membrane-associated lipoprotein on the live rBCG vac- 
cine vehicle. It is possible that this is the result of adjuvant 
effects provided by the BCG cell wall,  and/or a persistent 
"slow release" of OspA antigen by the live rBCG vaccine, 
which may continually restimulate 'he immune response as 
the organism persists  or grows in the host. 
These studies have provided the first demonstration of pro- 
tection elicited by a recombinant BCG vaccine and the devel- 
opment  of  a  promising  candidate  vaccine  for  the  im- 
munoprophylaxis of Lyme disease. Delivery of OspA as a 
lipoprotein in the live replicating rBCG vector not only ob- 
viates the need to purify and formulate sufficient quantities 
of an OspA subunit vaccine, but rBCG delivery may also 
elicit more uniform responses in vaccinees of a heterogeneous 
genetic background. Further studies are necessary to deter- 
mine whether the immunogenicity of other lipoprotein and 
nonlipoprotein target antigens can be enhanced by delivery 
as chimeric membrane-associated lipoproteins on rBCG. We 
are also investigating whether this approach will also enhance 
cellular  immune responses  to target antigens delivered by 
rBCG. Such studies could illuminate the mechanism by which 
lipid modification or membrane-associated expression can aug- 
ment antigen immunogenicity. 
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